Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 152 recruiting now full pipeline #8 of 28,707 conditions

Hypertension: full-pipeline trial registry

152 of 472 indexed Hypertension trials are currently recruiting.

Corpus placement: #8 of 28,707 conditions by registered trial count.

472 US clinical trials · 152 currently recruiting · #8 of 28,707 conditions by registered trial count

Hypertension: 472 US clinical trials tracked, 152 recruiting.

Hypertension is the subject of 472 registered US clinical trials on ClinicalTrials.gov, 152 of them currently open to new participants. 65 are in Phase 3-4 (later-stage) and 64 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 15 of these trials.

Enrollment posture brief

Registry condition hypertension

OPEN 152 | RECR 32% | LATE 65 | EARLY 64 | RANK #8 | SPON 15

Nearest open-share peer: Leukemia, Myeloid, Acute (32% recruiting · 31 trials)

Stroke47.8%Non-Small Cell Lung Cancer45.3%Multiple Myeloma37.9%Lung Cancer34%Hypertension (this)32%
Open-enrollment share among volume-matched conditions near Hypertension

Hypertension lists 152 open slots (32% of 472 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hypertension on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hypertension is recruiting below its size-band peers.

    152 of 472 indexed trials (32.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Hypertension trials is spread across many organizations.

    Johns Hopkins University accounts for 15 of 472 trials (3.2%). 195 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hypertension enrolment sits around 168 participants.

    Median target enrolment is 168 among the 471 trials that report a genuine target (sentinel values excluded). 170 of those (36.1%) plan for fewer than 100 participants.

  4. Hypertension research is mostly interventional.

    407 interventional and 65 observational studies make up this index (86.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 139Phase 225Phase 337Phase 428

Open and recent trials

472 total, page 7 of 10

COMPLETED NA 300 participants

Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients

Massachusetts General Hospital

NCT02551640

COMPLETED NA 300 participants

Group Visits to Improve Hypertension Management

US Department of Veterans Affairs

NCT00129493

COMPLETED NA 298 participants

A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention

Case Western Reserve University

NCT03643705

COMPLETED NA 295 participants

Health Coach Program to Improve Chronic Disease Outcomes Following an Emergency Department Visit

Alameda County Medical Center

NCT02386540

COMPLETED NA 290 participants

Improving Blood Pressure in Colorado

Kaiser Permanente

NCT00520988

COMPLETED Phase 2 285 participants

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Mineralys Therapeutics

NCT05769608

COMPLETED NA 278 participants

A Randomized Trial of Changing Medication Adherence In Hypertensive African-American Patients

Weill Medical College of Cornell University

NCT00248872

COMPLETED Phase 4 278 participants

A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension

Daiichi Sankyo

NCT00430638

COMPLETED Phase 2 270 participants

Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women

National Heart, Lung, and Blood Institute (NHLBI)

NCT00666172

COMPLETED NA 270 participants

Mechanisms Underlying the Blood Pressure Lowering Effect of Sleep

Beth Israel Deaconess Medical Center

NCT03043963

COMPLETED NA 254 participants

Veterans Walk for Health Study

US Department of Veterans Affairs

NCT00123435

COMPLETED NA 253 participants

RCT of Effects of Device-guided Breathing on Ambulatory BP

Rutgers, The State University of New Jersey

NCT01184755

COMPLETED NA 251 participants

Social Risk Score, Clinical Decision Support Tool and Closed Loop Referral for Social Risk Screen and Referral

Johns Hopkins University

NCT05574699

COMPLETED Phase 3 250 participants

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

Novartis

NCT00171405

COMPLETED NA 250 participants

Remote Monitoring and Social Support for Hypertension Management

University of Pennsylvania

NCT03416283

COMPLETED Phase 3 239 participants

Can Group Visits Improve Outcomes of Veterans With Diabetes

US Department of Veterans Affairs

NCT00286741

COMPLETED 234 participants

DETECT and Retinal Outcomes in Hypertension

Emory University

NCT01815567

COMPLETED NA 220 participants

A ED-based Intervention to Improve Antihypertensive Adherence

Vanderbilt University

NCT02672787

COMPLETED NA 220 participants

Expanding Technology-Enabled Nurse Delivered Chronic Disease Care

Duke University

NCT05120544

COMPLETED 210 participants

Epidemiology of Hypertensive Emergency

Columbia University

NCT00005240

COMPLETED NA 210 participants

Medically Tailored Groceries and Food Resource Coaching

University of Texas Southwestern Medical Center

NCT06242808

COMPLETED Phase 3 208 participants

An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

Novartis Pharmaceuticals

NCT01151410

COMPLETED NA 204 participants

Patient Centered Health Technology Medication Adherence Program for African American Hypertensives

Medical University of South Carolina

NCT03454308

COMPLETED Phase 4 203 participants

Smoking Study With Behavioral Therapy for Hypertensive Patients

UConn Health

NCT00879177

COMPLETED NA 200 participants

Federal Study of Adherence to Medications in the Elderly (FAME)

Walter Reed Army Medical Center

NCT00393419

COMPLETED 200 participants

Real-world Aliskiren Use in Diabetic Patients

Novartis

NCT01393860

COMPLETED 200 participants

Perioperative Blood Pressures and Chronic Hypertension

Yale University

NCT02136810

COMPLETED NA 196 participants

CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes

University of Massachusetts, Worcester

NCT01416766

COMPLETED NA 187 participants

Quality IQ Patient Simulation Physician Practice Measurement and Engagement

Qure Healthcare

NCT03800901

COMPLETED NA 185 participants

Renin Profiling in Selection of Initial Antihypertensive Drug

The Louis & Rachel Rudin Foundation

NCT00834600

COMPLETED NA 182 participants

Effect of a Secure Message Reminder on Hypertension Follow-up at an Integrated Health Care System

Kaiser Permanente

NCT01952119

COMPLETED 179 participants

Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery

Columbia University

NCT01140854

COMPLETED Phase 2 175 participants

Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

AstraZeneca

NCT05459688

COMPLETED 168 participants

Impact of Community Health Workers on Adherence to Therapy for Non-Communicable Chronic Disease in Chiapas, Mexico

Brigham and Women's Hospital

NCT02549495

COMPLETED Phase 4 166 participants

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

University of Texas Southwestern Medical Center

NCT00353652

COMPLETED NA 160 participants

Veteran Preference For Group Visits and Its Effect on Hypertension Outcomes

US Department of Veterans Affairs

NCT00439816

COMPLETED Phase 2 160 participants

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure

Ionis Pharmaceuticals

NCT04714320

COMPLETED NA 159 participants

Achieving Blood Pressure Control Together Study

Johns Hopkins University

NCT01902719

COMPLETED Phase 1 152 participants

Treatment of Supine Hypertension in Autonomic Failure

Vanderbilt University

NCT00223717

COMPLETED NA 152 participants

Internet-based Diabetes Education and Case Management

US Department of Veterans Affairs

NCT00105898

COMPLETED NA 149 participants

Evaluating a Web-Based Cardiovascular Disease Risk Factor Reduction Program Among American Indians

Black Hills Center for American Indian Health

NCT00608387

COMPLETED NA 148 participants

Heart Health 4 New Moms: A Randomized Trial in the First Year After Preeclampsia

University of Pittsburgh

NCT03749746

COMPLETED NA 146 participants

Radio Stories About Children's Healthy Eating and Exercise

University of Minnesota

NCT02139787

COMPLETED Phase 2 143 participants

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

Esperion Therapeutics

NCT02178098

COMPLETED NA 139 participants

Achieving Blood Pressure Control Through Enhanced Discharge

Wayne State University

NCT02069015

COMPLETED NA 136 participants

Take Charge of Your Diabetes

University of Pennsylvania

NCT01977495

COMPLETED NA 134 participants

ARMS: The Arm Rest and Support Study

Johns Hopkins University

NCT05372328

COMPLETED Phase 4 124 participants

Salt Loading and Thiazide Intervention Study

University of Maryland, Baltimore

NCT00896389

COMPLETED Phase 2 122 participants

Mechanisms and Therapeutic Effects of the Relaxation Response in Elderly Hypertensive Patients

Beth Israel Deaconess Medical Center

NCT00179543

COMPLETED NA 118 participants

Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients

Providence VA Medical Center

NCT00357955

← Previous Page 7 of 10 Next →

Phase Distribution

PhaseTrial count
Phase 1 39
Phase 2 25
Phase 3 37
Phase 4 28

Named interventions

Most-linked intervention names on Hypertension records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
30 trials
Amlodipine Drug
7 trials
Nebivolol Drug
5 trials
Eplerenone Drug
4 trials
Valsartan Drug
4 trials
Ramipril Drug
4 trials
Usual care Other
4 trials
Saline Drug
4 trials

US sites by state

Facility locations filed on Hypertension trials. A trial with sites in several states counts in each.

California 84 trials
Florida 53 trials
Massachusetts 49 trials
New York 47 trials
Illinois 47 trials
Alabama 43 trials
North Carolina 41 trials
Maryland 40 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hypertension page

472 registered trials, 152 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypertension condition card totals 472 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.